secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K/A
Filed at:   2021-12-06T23:59:59+00:00
Accession:  0001104659-21-146806
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma enters consulting agreement with departing SVP; equity awards to vest
--------------------------------------------------------------------------------

- Vijay Sabesan, SVP Technical Operations, left effective Nov 30, 2021 as previously reported.
- On Nov 30, 2021, Company and Sabesan entered a consulting agreement to facilitate transition.
- Certain outstanding equity awards will vest under the consulting agreement; no dollar amount disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465921146806/0001104659-21-146806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465921146806/tm2134621d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-146806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer